Transcatheter Tricuspid Valve Replacement
DeviceReplacement of the tricuspid valve through a transcatheter approach
Other names: Edwards EVOQUE Tricuspid Valve Replacement System
NCT Number: NCT04221490
Prospective, multi-center study to assess safety and performance of the Edwards EVOQUE Tricuspid Valve Replacement System
This study is active but is not currently recruiting participants.
18 year and older
All sexes
Interventional
Not applicable
St. Paul's Hospital Vancouver, Vancouver, British Columbia, Canada
The study is a multi-center, prospective single arm study designed to evaluate the safety and performance of the Edwards EVOQUE Tricuspid Valve Replacement System.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Key Inclusion Criteria:
Key Exclusion Criteria:
Replacement of the tricuspid valve through a transcatheter approach
Other names: Edwards EVOQUE Tricuspid Valve Replacement System
Time frame: 30 Days
Composite of major adverse events (MAE) defined as cardiovascular mortality, myocardial infarction, stroke, renal complications requiring unplanned dialysis or renal replacement therapy, severe bleeding, unplanned or emergency tricuspid valve re-intervention, major access site and vascular complications, major access site and vascular complications, and device-related pulmonary embolism at 30 days.
Time frame: Intraprocedural
Study device is deployed as intended and the delivery system is successfully retrieved as intended at the time of the patient's exit from the cardiac catheterization laboratory.
Time frame: Discharge (Up to 7 days post procedure)
Device success without clinically significant paravalvular leak (PVL) on a transthoracic echocardiogram (assessed by the echo core lab) at time of discharge.
Time frame: 30 Days
Procedural success without MAEs at 30 days.
Time frame: Discharge (Up to 7 days post procedure)
Percentage of patients with at least 1 grade reduction in tricuspid regurgitation (TR) as measured by using a 5-grade classification system (mild, moderate, severe, massive, torrential). TR grade is assessed by an independent echocardiography core laboratory.
Time frame: Baseline, 30 Days, 6 Months
Tricuspid regurgitation (TR) is measured by transthoracic echocardiogram (TTE) at each visit using a 5-grade classification system (mild, moderate, severe, massive, torrential). TR grade is assessed by an independent echocardiography core laboratory.
Time frame: Baseline, 30 Days, 6 Months
NYHA Functional Classification - The stages of heart failure:
Class I - No symptoms and no limitation in ordinary physical activity Class II - Mild symptoms and slight limitation during ordinary activity. Class III - Marked limitation in activity due to symptoms, even during less-than-ordinary activity. Comfortable only at rest.
Class IV - Severe limitations. Experiences symptoms even while at rest.
Time frame: 30 Days, 6 Months
Mean distance in meters walked during Six Minute Walk Test (6MWT) at each follow-up visit compared to baseline. 6MWT is a submaximal exercise test that measures the distance that a patient can walk on a flat surface in a period of 6 minutes.
Time frame: 30 Days, 6 Months
Mean KCCQ score at each follow-up visit compared to baseline. The KCCQ is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. Scores range from 0-100, in which higher scores reflect better health status.
Time frame: 30 Days, 6 Months
Mean change in SF-36 mental score at each follow-up visit compared to baseline compared to baseline. The SF-36 questionnaire consists of eight scales yielding two summary measures: physical and mental health. The mental health measure is composed of vitality (4 items), social functioning (2 items), role-emotional (3 items), and mental health (5 items). Scores are transformed to a range of 0-100, in which higher scores reflect better health status.
Time frame: 30 Days, 6 Months
Mean change in SF-36 physical score at each follow-up visit compared to baseline. The SF-36 questionnaire consists of eight scales yielding two summary measures: physical and mental health. The physical health measure includes four scales of physical functioning (10 items), role-physical (4 items), bodily pain (2 items), and general health (5 items). Scores are transformed to a range of 0-100, in which higher scores reflect better health status.
Time frame: 30 Days, 6 Months
Mean change in body weight in kilograms at each follow-up visit compared to baseline.
Time frame: 30 Days, 6 Months
Mean change in left ankle circumference in centimeters at each follow-up visit compared to baseline.
Time frame: 30 Days, 6 Months
Mean change in right ankle circumference in centimeters at each follow-up visit compared to baseline.
Time frame: Baseline, 30 Days, 6 Months
The edema grading scale measures how quickly the dimple goes back to normal (rebound) after a pitting test. The scale includes:
Grade 1: Immediate rebound with 0 to 2 millimeter (mm) pit. Grade 2: Less than 15-second rebound with 3 to 4 mm pit. Grade 3: Rebound greater than 15 seconds but less than 60 seconds with 5 to 6 mm pit.
Grade 4: Rebound between 2 to 3 minutes with an 8 mm pit.
Edwards Lifesciences
Industry
Edwards EVOQUE Tricuspid Valve Replacement: Investigation of Safety and Clinical Efficacy After Replacement of Tricuspid Valve With Transcatheter Device
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04482062
Cardiovascular Diseases, Heart Diseases
Phoenix, Arizona, United States
View Trial DetailsNCT05760989
Cardiovascular Diseases, Heart Diseases
Kitakyushu-shi, Fukuoka, Japan
View Trial DetailsNCT06506942
Cardiovascular Diseases, Heart Diseases
Atlanta, Georgia, United States
View Trial DetailsNCT06458907
Cardiovascular Diseases, Heart Diseases
Birmingham, Alabama, United States
View Trial Details